Loading stock data…
Viking Therapeutics (VKTX)
$39.54+1.50 (+3.94%)
After Hours$39.49-0.05 (-0.13%)· Last close Jun 29
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Viking Therapeutics, Inc. in the Healthcare sector is trading at $39.54 with a market capitalization of $3.4B. Wall Street consensus targets $92.58 (19 analysts), implying a +134.1% move over the next 12 months. The stock is currently near its 52-week high of $43.15, remaining 20.8% above its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals, Altman Z in the safe zone. The Whystock Score of 90/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +134.1% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$164.13M↑ | -$164.74M↓ | -$98.56M↓ | -$74.57M↓ | -$55.47M |
| Net Income | -$158.32M↓ | -$157.66M↓ | -$90.79M↓ | -$65.56M↓ | -$45.63M |
Peer Comparison
JNJUNHPFE
Fundamentals
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective a...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$3.39B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-94.11%
Volume
Today's trading volume
2.88M
Recent News
Novo Nordisk vs. Viking: Which Obesity Drug Stock Is the Better Buy?
NVO and VKTX stocks offer contrasting opportunities in the fast-growing obesity market, with key differences in growth, risk and pipeline strength.
Is It Worth Investing in Viking Therapeutics (VKTX) Based on Wall Street's Bullish Views?
The average brokerage recommendation (ABR) for Viking Therapeutics (VKTX) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?
Dyne Therapeutics vs. Viking Therapeutics: Which Healthcare Stock Is a Better Buy in 2026?
Dyne is advancing therapies for rare muscle diseases while Viking targets the booming weight-loss market. See how their financials and risk profiles compare.
Viking Therapeutics (VKTX) Starts First Human Obesity Trial For VK3019
Viking Therapeutics (NasdaqCM:VKTX) has begun a Phase 1 clinical trial for VK3019, a dual amylin and calcitonin receptor agonist targeting obesity. The study marks the first human testing of VK3019 and expands the company’s metabolic disorder pipeline beyond its existing GLP-1/GIP candidates. The program adds another potential obesity treatment approach that uses different biological pathways from current GLP-1 focused therapies. Viking Therapeutics, traded as NasdaqCM:VKTX, is building out...
Viking Therapeutics, Inc. (VKTX) Sees a More Significant Dip Than Broader Market: Some Facts to Know
In the closing of the recent trading day, Viking Therapeutics, Inc. (VKTX) stood at $36.97, denoting a -2.38% move from the preceding trading day.